Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 5,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the sale, the insider now owns 69,184 shares of the company’s stock, valued at approximately $940,210.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Amicus Therapeutics, Inc. (FOLD) traded down $0.23 during mid-day trading on Wednesday, reaching $12.51. The company had a trading volume of 2,193,500 shares, compared to its average volume of 3,185,740. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same period last year, the business earned ($0.33) EPS. The firm’s quarterly revenue was up 419.0% on a year-over-year basis. equities research analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on FOLD. Zacks Investment Research lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Goldman Sachs Group reissued a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a research report on Friday, October 6th. Chardan Capital reissued a “buy” rating and issued a $18.50 target price (up previously from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Robert W. Baird reissued an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Finally, J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $17.81.

Hedge funds have recently bought and sold shares of the stock. Strs Ohio bought a new position in Amicus Therapeutics during the 3rd quarter valued at approximately $102,000. Teacher Retirement System of Texas increased its position in Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 169 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $124,000. Aperio Group LLC increased its position in Amicus Therapeutics by 13.5% during the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management bought a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $145,000.

COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Insider Jay Barth Sells 5,000 Shares” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/06/amicus-therapeutics-inc-fold-insider-jay-barth-sells-5000-shares.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.